Discover our new website and eShop

Our new site is easier to use, mobile-friendly, and personalized.

Learn more about the
Nucleofector™ Technology

Identify potential drug targets in virtually any cell type which is relevant for your cancer research by using Lonza’s Nucleofector™ Technology. Our higher throughput platforms, i.e. the 96-well Shuttle™ Add-on or the 384-well HT Nucleofector™ System provide the ideal tool to perform siRNA or cDNA screens in hard-to-transfect cell lines or primary cells.

Efficient non-viral transfection
  • Up to 90% transfection efficiency for primary cells and difficult-to-transfect cancer cell lines, including blood, breast and prostate cancer
  • Combined with high cell viability

High flexibility

  • Same protocol for transfecting DNA, RNA or siRNA
  • LHS compatible 96-well or 384-well platforms, for e.g. siRNA screenings

Proven technology

  • Minimal optimization effort due to availability of more than 100 ready-to-use Nucleofection™ Protocols
  • More than 800 cancer-related publications

Basics about Nucleofector™ Technology
Nucleofection™ is a technology based on the momentary creation of small pores in cell membranes by applying an electrical pulse. The comprehensive way in which Nucleofector™ Programs and cell type-specific solutions are developed enables nucleic acid substrates delivery not only to the cytoplasm, but also through the nuclear membrane and into the nucleus. This allows for high transfection efficiencies up to 99% and makes the transfection success independent from any cell proliferation.

Developed in 1998, the Nucleofector™ Technology was introduced to the research market in 2001 as the first efficient non-viral transfection method for primary cells and hard-totransfect cell lines. With the Nucleofector™ Technology primary cells and stem cells, as well as cell lines, can be consistently transfected at high efficiency. Since then the technology has evolved through constant innovation.